Peptide Research, Explained
Everything on this site assumes you know roughly what "preclinical" or "Phase II" means. This page is where that gets explained properly — so you can judge the evidence on any compound, not just take our word for it.
What is a peptide, actually?
A peptide is a short chain of amino acids — the same building blocks that make up proteins — linked together by peptide bonds. The dividing line between "peptide" and "protein" is mostly just size: once a chain gets long enough (roughly 50 or more amino acids), it's usually called a protein instead.
Because they're small, peptides are relatively cheap and precise to synthesise compared to larger proteins, which is a big part of why there are so many of them in research labs: they're a practical way to study specific biological signalling pathways without the complexity of a full protein.
Why are they studied in the first place?
Peptides occur naturally throughout the body as signalling molecules — hormones, neurotransmitter modulators, immune signals. Researchers study synthetic versions for a few overlapping reasons: to understand how a natural signalling pathway works, to see whether amplifying or blocking that pathway has a measurable effect in a model system, and sometimes as an early step toward an eventual approved drug.
Most peptides that get studied never become an approved medicine. That's normal, not a failure — most research compounds in any field don't. It's part of why the evidence ladder further down this page matters: being "studied" and being "established" are very different points on a long road.
In vitro vs. in vivo
Two Latin terms you'll see on almost every paper — they describe where the study actually took place, which changes how much weight the result should carry.
In vitro — "in glass"
Cells or tissue studied outside a living organism — in a petri dish or test tube. Fast, cheap, and tightly controlled, which makes it a good first look at whether something does anything biologically interesting at all. It tells you almost nothing about how a whole living body would respond.
In vivo — "within the living"
Studied inside a living organism — almost always an animal model at this stage. Slower and more expensive than in vitro work, but it accounts for things a dish can't: metabolism, circulation, immune response, whole-body dosing. Still not human evidence.
Animal evidence vs. human evidence
A result that holds up in rodents is a legitimate reason to keep studying something — it is not evidence that the same thing happens in people. Dosing doesn't scale simply between species, metabolism differs, and plenty of compounds that looked promising in animal models have shown no effect, or an unwanted one, once tested in humans.
This is the single most common gap papered over in online discussion of research peptides: animal-model findings get described in language that implies human relevance it hasn't earned yet. Our BPC-157 deep dive on the homepage is a direct example of a compound with a strong animal literature and almost no human trial data — worth reading alongside this section.
Clinical trial phases, properly explained
Phase I
A small group — often a few dozen people. The question isn't "does it work," it's "is it safe, and at what dose." Most compounds that reach this stage are still years from any approval decision.
Phase II
A larger group, now looking at effect as well as safety — does it actually do the thing it's meant to, and at what dose does that hold up without unacceptable side effects.
Phase III
Large-scale, usually comparing against an existing treatment or a placebo. This is the evidence regulators actually weigh when deciding whether to approve something.
Phase IV
Monitoring after approval, in the general population, over a longer time period — catching rare side effects a smaller trial wouldn't have the numbers to detect.
Most compounds discussed in the research-peptide space have never reached a registered Phase I trial. That's not automatically disqualifying — plenty of legitimate research never needs to go there — but it's a fact worth knowing before reading claims about "clinical results."
What "mechanism" actually means
When a paper says a compound "acts through" a particular receptor or signalling pathway, it's describing the proposed biological chain of cause and effect — compound binds to X, which triggers Y, which produces the observed result. Understanding the mechanism is genuinely useful: it's how researchers predict where else a compound might matter, and it's how unexpected effects get explained after the fact.
What a plausible mechanism doesn't do is substitute for an actual measured outcome. A compound can have a well-understood, entirely real mechanism in a cell model and still do nothing measurable in a whole organism, for reasons that have nothing to do with whether the mechanism itself is real.
The stats basics worth actually knowing
You don't need a statistics degree. You need these four ideas.
Sample size (n)
How many subjects (people, animals, or samples) the result is based on. A finding in 8 mice and a finding in 800 people carry very different weight, even if the headline sounds the same.
Statistical significance
Usually reported as a p-value. It tells you how likely the result is to be random chance — it does not tell you how large or meaningful the effect actually is. Small, unimportant effects can still be "statistically significant" in a large enough sample.
Effect size
How big the actual difference was — the number that tells you whether an effect is meaningful, separate from whether it was statistically real. Papers that lead with significance and bury effect size are worth a second look.
Confidence interval
A range, not a single number — the study's honest estimate of how much the true result could vary. A wide interval usually means the sample was too small to be confident about the exact number.
Why studies on the same compound sometimes disagree
Conflicting results are normal, not a sign something is broken. The usual causes: different doses or administration routes, different animal strains or human populations, different outcomes actually being measured, different study durations, and plain statistical noise in small samples. Publication bias plays a role too — studies finding a positive effect are historically more likely to get published than ones finding nothing, which can skew the literature that's easiest to find.
When you see two studies that appear to contradict each other, the useful question isn't "which one is right" — it's "what was actually different about how they were run."
What peer review does — and doesn't — check
Peer review means other researchers in the field read the methodology before publication and judged it sound enough to publish. It catches obvious design flaws, missing controls, and claims the data doesn't support. It does not mean the finding has been replicated, that it generalises beyond the specific model studied, or that the study is free of the author's own biases. It's a quality floor, not a truth stamp.
Limitations worth watching for
None of these automatically invalidate a study — but each one should lower how much weight you put on a claim built from it.
Small sample sizeFindings from a handful of subjects are a starting point, not a conclusion.
No control groupWithout something to compare against, you can't separate a real effect from coincidence.
Animal-only evidenceReal and useful — but not evidence of a human effect, as covered above.
Single, unreplicated studyOne result is a data point. Science relies on other labs reproducing it.
Preprint, not peer-reviewedPreprints are useful but haven't cleared the quality check peer review provides yet.
Funded by an interested partyNot disqualifying by itself — but worth knowing, same as our own disclosure on this site.
The ladder we use on every compound
This is the same scale behind every tier shown in the Evidence Library — five rungs, each one a meaningfully higher bar than the last.
Lab & in vitro
Cell or tissue studies outside a living organism. Establishes that something biologically interesting is happening at all — the floor of the ladder, not the roof.
Animal (in vivo)
Whole-organism studies, almost always rodent models at this stage. Accounts for metabolism and systemic effects a dish can't — still not evidence of a human effect.
Early human evidence
Small, often uncontrolled human studies or early-phase trials. The first real signal of how this behaves in people — not yet enough to draw firm conclusions.
Larger controlled trials
Properly controlled, adequately powered human trials — the kind of evidence that can actually support a claim about effect, not just plausibility.
Established evidence
Replicated across multiple independent trials, generally accepted within the field. Very few research peptides currently sit here — most of the compounds discussed in this space sit at Level 1 or 2.
The Primary Source, including this page, is produced and funded by Reliable Research Labs, a UK research-peptide supplier. This page contains no product recommendations, no dosing information, and no sales content — it exists so you can evaluate evidence on any compound, from any supplier, more critically. Read the full disclosure →